Achillion Pharma (ACHN) Announces Prelim. Proof-of-Concept With ACH-4471 for Treatment of C3G
Tweet Send to a Friend
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today reported preliminary proof-of-concept results from group 1 of its ongoing Phase 2, open-label, 14-day ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
